By ATDBio
Therapeutic oligos often require specialised chemistries to improve stability, potency, delivery and overall performance. ATDBio supports a wide range of established and emerging modification strategies, helping developers tailor oligos to the specific requirements of their project. Sugar modifications Common sugar modifications for therapeutic oligonucleotides include RNA, 2'-methoxy (2'-OMe) RNA, 2'-F RNA, 2'-methoxyethyl (2'-MOE) RNA, LNA and constrained ethyl (cEt), in addition to standard DNA. Backbone modifications Common backbone modifications include phosphorothioate (PS), phosphorodithioate (PDS), methylphosphonate (MeP), phosphoramidates (PA) and mesyl phosphoramidate (MsPA), in addition to the standard phosphodiester (PO) DNA backbone. 5'- and 3'-modifications Common 5'- and 3'-modifications in therapeutic oligonucleotides include 5'-(E)-vinylphosphonate (5'-(E)-VP), a metabolically stable phosphate mimic that improves the in vivo stability and potency of siRNAs. Lipophilic modifications (including 5'-cholesterol and 5'-palmitate) for improved cellular uptake. GalNAc A range of off-the-shelf and custom trivalent 5'- and 3'-GalNAc (N-acetylgalactosamine) modifications enable targeted delivery of ASOs and siRNAs to the liver.
